Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations
Clinical trial NCT05082025 · TERMINATED
Trial details
- NCT number
- NCT05082025
- Sponsor
- M.D. Anderson Cancer Center
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-09-27
- Primary completion
- 2024-05-03
- Enrollment
- 7
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.